Ashley McKhann Selected Research

Isoniazid (Ftivazide)

4/2024

High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ashley McKhann Research Topics

Disease

5	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 01/2019
1	Tuberculosis (Tuberculoses) 04/2024
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 04/2024
1	Neoplasms (Cancer) 03/2024
1	Cryptococcal Meningitis 01/2023
1	Disease Progression 03/2022
1	Viremia 01/2022
1	Parasitemia 01/2022
1	Inflammation (Inflammations) 12/2021
1	Herpes Zoster 10/2019
1	Stroke (Strokes) 01/2019
1	Myocardial Infarction 01/2019

Drug/Important Bio-Agent (IBA)

1	Isoniazid (Ftivazide)FDA LinkGeneric 04/2024
1	cemiplimabIBA 03/2024
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2023
1	Fluconazole (Zonal)FDA LinkGeneric 01/2023
1	Immune Checkpoint ProteinsIBA 03/2022
1	Lopinavir FDA Link 01/2022
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Reverse Transcriptase InhibitorsIBA 01/2022
1	Ritonavir (Norvir)FDA Link 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2020

Therapy/Procedure

6	Therapeutics 03/2022 - 01/2019
2	Art Therapy 12/2021 - 01/2019